ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2020
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom.
Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Cost of the COVID-19 pandemic versus the cost-effectiveness of mitigation strategies in EU/UK/OECD: a systematic review.BMJ open · 2023Pooled it
- Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.Journal of global health · 2022Pooled it
- Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Pooled it
- Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Pooled it
- The Association between COVID-19 Status and Economic Costs in the Early Stages of the COVID-19 Pandemic: Evidence from a UK Symptom Surveillance Digital Survey.PharmacoEconomics - open · 2025Article
- Epidemiological and health economic implications of symptom propagation in respiratory pathogens: A mathematical modelling investigation.PLoS computational biology · 2024Article
- The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model.BMC health services research · 2023Article
- Cost-effectiveness analysis of vaccination against COVID-19 in China.Frontiers in public health · 2023Article
- Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: a modelling and economic analysis study.BMC health services research · 2022Article
- State-controlled epidemic in a game against a novel pathogen.Scientific reports · 2022Article
- Economic evaluations of interventions against viral pandemics: a scoping review.Public health · 2022Article
- Estimating US Earnings Loss Associated with COVID-19 Based on Human Capital Calculation.International journal of environmental research and public health · 2022Article
- Association of Simulated COVID-19 Policy Responses for Social Restrictions and Lockdowns With Health-Adjusted Life-Years and Costs in Victoria, Australia.JAMA health forum · 2021Article
- QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets.The patient · 2021Article
- Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Article
- Article
- The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19).Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to cost and calculate the relative cost-effectiveness of the hypothetical suppression policies found in the Imperial College COVID-19 Response Team model.
methodsKey population-level disease projections in deaths, intensive care unit bed days, and non-intensive care unit bed days were taken from the Imperial College COVID-19 Response Team report of March 2020, which influenced the decision to introduce suppression policies in the United Kingdom. National income loss estimates were from a study that estimated the impact of a hypothetical pandemic on the UK economy, with sensitivity analyses based on projections that are more recent. Individual quality-adjusted life-year (QALY) loss and costed resource use inputs were taken from published sources.
resultsImperial model projected suppression polices compared to an unmitigated pandemic, even with the most pessimistic national income loss scenarios under suppression (10%), give incremental cost-effectiveness ratios below £50 000 per QALY. Assuming a maximum reduction in national income of 7.75%, incremental cost-effectiveness ratios for Imperial model projected suppression versus mitigation are below 60 000 per QALY.
conclusionsResults are uncertain and conditional on the accuracy of the Imperial model projections; they are also sensitive to estimates of national income loss. Nevertheless, it would be difficult to claim that the hypothetical Imperial model-projected suppression policies are obviously cost-ineffective relative to the alternatives available. Despite evolving differences between government policy and Imperial model-projected suppression policy, it is hoped this article will provide some early insight into the trade-offs that are involved.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.